Good deal compared to what? I've seen where a BP
Post# of 72440
I've seen where a BP paid $700M for a preclinical drug that failed miserably and I'm sure there are others just like it.
How high is UP is another good question.
We are not dealing with a reformulated drug nor are we dealing with another "new" antibiotic in the cycline or mycin family.
If this was just "another drug" addressing an indication in an already competitive market,value assessment would be much easier.
However:
We are dealing with a whole new class of drug that addresses an unmet need in a totally and potentially vast untouched market .
We are dealing with a drug that so far has not shown any meaningful contraindications,side affects,or adverse reactions.What are "No Lawsuits" worth to a BP?
We are dealing with a drug that is easily administered,packaged,shipped and stored.What's that worth?
We are dealing with a drug that will be rapidly accepted by the medical community as well as the insurance industry.What's that worth?
We are dealing with a drug that will likely have global marketing from the start.What's that worth?
To quantify that in dollars and cents is not only above my "pay grade" but also likely far above yours as well.
Best not to talk about deal values and leave that up to those who know far more than any of us do.
Kelt